ABVC BioPharma, Inc. Common Stock
ABVC BioPharma, Inc., a clinical-stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials as a combination therapy for triple-negative breast cancer; ABV-1504, which has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601, which is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus, which is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. ABVC BioPharma, Inc. is headquartered in Fremont, California, and operates as a subsidiary of YuanGene Corporation.
Open ABVC dashboard ↗Xencor, Inc.
Xencor, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibodies for the treatment of asthma and allergic diseases, autoimmune diseases, and cancer. The company provides Ultomiris to treat patients with atypical hemolytic uremic syndrome, generalized myasthenia gravis, neuromyelitis optica spectrum disororder; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma; and Sotrovimab that targets the SARS-CoV-2 virus. It develops XmAb819, a bispecific antibody to treat renal cell carcinoma; XmAb541, which is in Phase I for the treatment of ovarian cancer; XmAb808, a bispecific antibody that binds to the broadly expressed tumor antigen; Vudalimab, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer; XmAb564, to treat autoimmune diseases; XmAb662, which is in Phase I clinical trial to treat patients with solid tumors; XmAb942, which is in Phase I clinical trial for patients with Crohn's disease and ulcerative colitis; and Plamotamab, a bispecific antibody, which is in Phase I clinical trial to treat lymphoma. Further, the company develops Xaluritamig, a bispecific T-cell engager that treats prostate cancer; Obexelimab, to treat patients with immunoglobulin G4-related disease; Teropavimab and zinlirvimab to treat human immunodeficiency virus; Tobevibart, a treatment for hepatitis Delta virus infection; Novartis, an antibody drug candidate that uses XmAb Fc technologies; Xpro1595 to treat patients with Alzheimer's disease and treatment-resistant depression; Zaltenibart to treat paroxysmal nocturnal hemoglobinuria and other alternative pathway disorders; ASP2138 to treat gastric, gastroesophageal junction, and pancreatic cancers; JNJ-9401 to treat prostate cancer; and JNJ-1493 to treat B-cell malignancies. The company was incorporated in 1997 and is headquartered in Pasadena, California.
Open XNCR dashboard ↗